Cambridge Semantics, the leading provider of modern, graph-driven data integration for the enterprise data fabric, today announced that the U.S. Food and Drug Administration (FDA) has selected Cambridge Semantics as the analytics and integration layer for the FDA's Intelligent Data Lake.    

The FDA's Center for Drug Evaluation and Research (CDER) has begun a new strategic initiative to enhance its enterprise data architecture and regulatory review. The Intelligent Data Lake, when complete, will provide a platform for integrating data for analytics and insights pertaining to new drug applications, generic formulations, risk evaluation, translational science, and pharmaceutical quality.

"Cambridge Semantics' Anzo enhances the data lake with the critical capability to rapidly blend and analyze data in support of multiple, diverse use cases," said a senior program leader at the FDA.    

"We are excited and proud to be chosen as the data integration platform to accelerate the FDA's digital strategy," said Chuck Pieper, Chairman, and CEO of Cambridge Semantics. "Our graph technology uniquely enables the speed and scale required to integrate data for large, distributed organizations like the FDA."

Cambridge Semantics' Anzo provides a modern, graph-driven data integration platform to connect and bring meaning to all enterprise data and enable virtually anyone in an organization – from skilled data scientists to novice business users – to develop analytics-ready data sets that combine any data from any system across the enterprise. Anzo drives digital transformation and enables deep business insights when an organization's data is highly distributed, vastly siloed, complex, and when users want answers to unanticipated questions at speed and scale.

"A principal advantage of Anzo over alternative solutions is that the FDA and their trusted consulting partners now model, integrate and visualize the data in a self-service manner," said Ben Szekely, Senior Vice President of Field Operations at Cambridge Semantics. "We have provided an efficient, focused field team to enable the FDA to execute many high-value use cases in a rapid, scalable, cost-effective manner. The FDA will also enjoy the flexibility of applying their trusted BI and analytics tools to the integrated data sets in Anzo."